biotech · Relapsed/Refractory Large B Cell Lymphoma · Relapsed/Refractory Multiple Myeloma · ALLO
Allogene Therapeutics
Allogene Therapeutics clinical programs — 0 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
South San Francisco, USA HQ
2017 Founded
208 Employees
Public company Type
ALLO · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2017
- Employees
- 208
- Programs
- 8
- Drugs
- 2
- Patents
- 16
Allogene Therapeutics projects
0 ClinicalTrials.gov programs sponsored by Allogene Therapeutics.
Allogene Therapeutics has 0 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
No programs matched
Frequently asked questions
How many clinical projects does Allogene Therapeutics have?
0 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.